Key result
Propranolol for infantile hemangioma linked to ~33-fold higher odds of sleep disorders, plus coldness and hypoglycemia.
Why the study?
Does propranolol use for infantile hemangioma generate disproportional adverse safety signals in real-world settings?
Observational (n=1,615)
Yes
Does propranolol use for infantile hemangioma generate disproportional adverse safety signals in real-world settings?
Effect estimate: ROR 32.67 (95% CI 27.73-38.49)
Real-world pharmacovigilance data from FAERS highlights significant safety signals for propranolol in infantile hemangioma, particularly sleep disorders, peripheral coldness, and hypoglycemia, underscoring the need for vigilant monitoring.
No takes yet. Share an insight, caveat, or question.
Calls for vigilant monitoring in treated infants; extends prior safety data with real-world pharmacovigilance signals.
Li et al. (2026) conducted an observational in Infantile hemangioma (n=1,615). Propranolol was evaluated on Disproportional adverse event signals (Reporting Odds Ratio) (ROR 32.67, 95% CI 27.73-38.49). Propranolol treatment for infantile hemangioma was associated with significant adverse event signals, most frequently sleep disorders (ROR 32.67), peripheral coldness (ROR 108.73), and hypoglycemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: